BioIVT Strengthens Biorepository and Advances Research with PrecisionMed Acquisition

BioIVT, a prominent global research partner and biospecimen solutions provider, has recently acquired PrecisionMed, LLC, a leading supplier of high-quality human biological material for genetics, drug discovery, biomarker research, and in vitro diagnostics. PrecisionMed, based in Carlsbad, CA, has been at the forefront of collecting biospecimens for neurology and oncology research for over 27 years. Notably, the company has developed and manages the largest, private, global repository of longitudinally collected human cerebrospinal fluid (CSF) samples for scientific research.

A Landmark Acquisition

With its latest acquisition of PrecisionMed, BioIVT demonstrates its commitment to lead the biospecimen industry through expertise and innovation. The partnership brings together two industry leaders, each contributing unique strengths, to amplify their collective ability to impact the research community positively.

Advancing Research and Patient Impact

PrecisionMed’s regulatory-compliant and privacy-protected biorepository houses an impressive collection of over 170,000 samples, including CSF, whole blood, serum, plasma, PBMCs, and urine. Collected under Institutional Review Board-approved clinical protocols, these high-quality, well-annotated biospecimens are sourced from an extensive network of donors and collection sites. Each biospecimen is complemented by detailed clinical data, empowering researchers with valuable insights into the donor’s diagnosis, demographics, family medical histories, treatment responses, and disease progression.

Recognized Contributions

The scientific community has widely acknowledged PrecisionMed’s contributions, with over 120 citations in reputable scientific journals. Notably, its collections have played crucial roles in U.S. NIH grants, U.S. FDA submissions, and subsequent U.S. FDA clearance for diagnostics. This underscores the invaluable role of PrecisionMed’s repository in advancing medical knowledge and accelerating the development of innovative diagnostics and therapies.

Executive Enthusiasm

BioIVT Chief Executive Officer Richard Haigh, PhD, expressed their excitement about BioIVT’s acquisition of PrecisionMed, stating that the company’s vision is to lead the biospecimen industry through expertise and innovation, and the acquisition of PrecisionMed brings them even closer to that goal. They look forward to the future possibilities as they expand their supply network and inventory to meet the increasing customer demand for cerebrospinal fluid (CSF) and liquid biopsy products. Richard Haigh emphasized that this partnership will drive greater value for customers and further their mission of enabling smarter science.

In response to the acquisition, PrecisionMed Co-CEO Eric Leach stated that the vision at PrecisionMed has always been centered around positively impacting patients’ lives through fueling innovation and scientific discovery. He acknowledged BioIVT as the gold standard in the industry with a strong track record and global reach. Eric Leach expressed pride in pairing PrecisionMed’s talent and resources with the world-class team at BioIVT, as this partnership magnifies their collective ability to reach the research community and impact patient lives.

Envisioning a Future Together

BioIVT and PrecisionMed Teams look forward to the boundless possibilities that lie ahead as they expand their supply network and inventory. With a shared vision of enabling smarter science and positively impacting patient lives, this partnership aims to drive even greater value for their customers and the research community. As BioIVT adds PrecisionMed to its portfolio, the latter will continue to operate from its existing headquarters and maintain its extensive network of donor and collection sites. The seamless integration of their resources and expertise promises to elevate scientific discovery and propel medical advancements to new heights.

About PrecisionMed

PrecisionMed stands as a leading supplier of high-quality human biological material for research, boasting the distinction of being the largest private global source of longitudinally collected human cerebrospinal fluid (CSF) from both living normal controls and diseased populations. Since its establishment in 1996, PrecisionMed’s accurately annotated human biological samples have been sought after and utilized by over 600 pharmaceutical and biotechnology companies, as well as academic research organizations worldwide.

Their meticulous, six-step collection process commences with the comprehensive validation of collection sites and concludes with customers owning 100% of the sample rights, free and clear. In addition, PrecisionMed ensures that every sample includes detailed donor data, encompassing diagnosis, demographics, donor family medical histories, treatment responses, and disease progression. True to their word, PrecisionMed delivers immediate availability of all samples, ensuring shipping within three (3) days.

PrecisionMed focuses on prospective longitudinal collections of blood products, cerebral spinal fluid, and malignant tissue, enabling researchers to gain valuable insights into disease progression and therapeutic response over time. PrecisionMed takes great pride in their adherence to the highest standards and stands firmly behind their products and services. Their long-term relationships with thoroughly vetted IRB-approved collection sites guarantee the provision of high-quality samples. Renowned research institutions, including Harvard Medical School, Biogen, and GlaxoSmithKline, regularly turn to PrecisionMed for their world-class biological material. With standardized procedures in place, PrecisionMed guarantees the quality of each sample, consistently providing the highest quality human biological material for research.

PrecisionMed’s reputation as a trusted sample source is solidified through numerous citations in scientific journals, attesting to their reliability and efficacy in supporting groundbreaking research studies worldwide. Upon purchase, every sample provided by PrecisionMed becomes the sole property of the customer, without any commercial incumbency. This means researchers retain 100% of the sample rights without the burden of paying royalties. Most importantly, PrecisionMed employs a predictive biobanking approach, constantly collecting samples to maintain a robust inventory ready for immediate shipping.

For more information, researchers can visit www.precisionmed.com to explore PrecisionMed’s vast array of high-quality, well-annotated human biological materials that contribute to advancing cutting-edge research and medical discoveries worldwide.

About BioIVT

BioIVT is a distinguished provider of high-quality personalized biospecimen solutions and research services to the life science and diagnostic industries. Renowned as an industry leader, BioIVT specializes in control and disease state samples, encompassing human and animal tissues or preparations, ADME-Tox products and research services, cell and gene therapy products, blood, and other biofluids.

BioIVT is driven by a mission to enable smarter science and accelerate medical breakthroughs. As a trusted partner in “ELEVATING SCIENCE®,” the company combines technical expertise and exceptional customer service with unparalleled access to biological specimens, serving as a valuable resource for the research community. BioIVT’s commitment to growth and excellence is evident in its acquisition of various industry leaders, including Ascendance Biotechnology, Asterand Bioscience, Celsis IVT, Clinical Trials Laboratory Services (CTLS), and many others. The BioIVT brand replaces the brand of each acquired affiliate and subsidiary.

BioIVT offers a suite of innovative technologies, including B-CLEAR®, HEPATOPAC®, HEPATOMUNE®, C-DILI™ Assay, TRANSPORTER CERTIFIED® Hepatocytes, OPTI-EXPRESSION® Technology, and LIVERPOOL® Hepatocytes. These cutting-edge methodologies empower clients in drug discovery, in vitro diagnostics, and ADME-Tox studies. BioIVT is unwavering in its commitment to providing high-quality human and animal biological products and related services. The company stands behind its specimens by offering an unconditional product guarantee. Moreover, BioIVT ensures world-class customer service before, during, and after shipment, supporting clients as true partners in their research endeavors.

BioIVT’s facilities hold globally recognized accreditations, including CDC Import Permits, NYS DOH Certificate, College of American Pathologists (CAP) certification, Authorized Economic Operator (AEO) status, ISO 9001:2015, Human Tissue Authority (HTA) licenses, and U.S. FDA registrations. BioIVT’s innovative technologies and unwavering commitment to quality position it as a formidable force in the advancement of medical research and the improvement of lives globally.

Find your perfect biospecimen. Visit bioivt.com now!

Engr. Dex Marco Tiu Guibelondo, BS Pharm, RPh, BS CpE

Editor-in-Chief, PharmaFEATURES